- Home
- TCMD vs FHTX Comparison
TCMD vs FHTX Comparison
Compare TCMD & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCMD | FHTX |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.1M | 247.1M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TCMD | FHTX |
|---|---|---|
| Price | $29.83 | $4.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $23.25 | $11.50 |
| AVG Volume (30 Days) | ★ 428.0K | 158.2K |
| Earning Date | 11-03-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.66 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $311,513,000.00 | $24,518,000.00 |
| Revenue This Year | $11.31 | $47.50 |
| Revenue Next Year | $8.83 | N/A |
| P/E Ratio | $38.58 | ★ N/A |
| Revenue Growth | ★ 9.28 | N/A |
| 52 Week Low | $8.61 | $2.95 |
| 52 Week High | $29.72 | $6.79 |
Technical Indicators
Market Signals| Indicator | TCMD | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 77.32 | 60.76 |
| Support Level | $28.00 | $4.21 |
| Resistance Level | $29.49 | $4.59 |
| Average True Range (ATR) | 1.02 | 0.28 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 98.93 | 83.13 |
Price Performance
Historical ComparisonAbout TCMD Tactile Systems Technology Inc.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.